Shanghai MicuRx Pharmaceutical Co., Ltd. (SHA:688373)

Market Cap	4.12B +36.1%
Revenue (ttm)	136.70M +13.9%
Net Income	-342.96M
EPS	-0.53
Shares Out	656.23M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	7,320,320
Average Volume	8,371,388
Open	6.36
Previous Close	6.36
Day's Range	6.26 - 6.36
52-Week Range	4.67 - 10.31
Beta	0.76
RSI	45.32
Earnings Date	Mar 28, 2026

About SHA:688373

Shanghai MicuRx Pharmaceutical Co., Ltd., a biopharmaceutical company, discovers, develops, and commercialize drugs for unmet medical needs. It is developing Contezolid (MRX-I) and Contezoilid acefosamil (MRX-4) oxazolidinone antibiotics for multidrug-resistant gram-positive bacteria; MRX-8 MRX, a polymyxin antibiotic, to target multidrug-resistant Gram-negative bacteria; MRX-5 for multidrug-resistant gram-negative bacteria; MRX-7 for multidrug-resistant gram-positive bacteria; MRX-15 and MRX-17 to treat kidney disease; MRX-18 for the treatment...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2007
• Employees: 177
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688373

Financial Performance

In 2024, SHA:688373's revenue was 130.27 million, an increase of 43.51% compared to the previous year's 90.78 million. Losses were -440.72 million, 4.65% more than in 2023.